<code id='D84D789645'></code><style id='D84D789645'></style>
    • <acronym id='D84D789645'></acronym>
      <center id='D84D789645'><center id='D84D789645'><tfoot id='D84D789645'></tfoot></center><abbr id='D84D789645'><dir id='D84D789645'><tfoot id='D84D789645'></tfoot><noframes id='D84D789645'>

    • <optgroup id='D84D789645'><strike id='D84D789645'><sup id='D84D789645'></sup></strike><code id='D84D789645'></code></optgroup>
        1. <b id='D84D789645'><label id='D84D789645'><select id='D84D789645'><dt id='D84D789645'><span id='D84D789645'></span></dt></select></label></b><u id='D84D789645'></u>
          <i id='D84D789645'><strike id='D84D789645'><tt id='D84D789645'><pre id='D84D789645'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:1374
          Checkpoint inhibitor
          Adobe

          ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

          The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

          advertisement

          iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more
          Infectious disease expert Jeanne Marrazzo assumes Fauci role
          Infectious disease expert Jeanne Marrazzo assumes Fauci role

          InfectiousdiseaseexpertJeanneMarrazzowilltakeAnthonyFauci'sjobatoptheNationalInstitutesofAllergyandI

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

          1:10PresidentJoeBidenparticipatesinaceremonialarrivalandinspectionofthehonorguardwithBritain'sKingCh